First Albany Ups Bioscrip to Buy from Neutral

Cites the company's quarterly results announcement last week.

First Albany raised its rating on Bioscrip (BIOS ) to buy from neutral, citing the company's quarterly results announcement last week.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.